Publication Date:
1994-05-06
Description:
Tumor immunotherapy should increase both the number of T cells that kill the tumor and the likelihood that those cells are activated at the tumor site. Bispecific monoclonal antibodies (Bi-mAbs) were designed that bound to a Hodgkin's tumor-associated antigen (CD30) on the tumor and to either CD3 or CD28 on the T cell. Immunodeficient mice were cured of established human tumors when mice were treated with both the CD3-CD30 and the CD28-CD30 Bi-mAbs and then given human peripheral blood lymphocytes that had been incubated with the CD3-CD30 Bi-mAb and cells that expressed CD30. The enrichment of human T cells within the tumor and the fact that established tumors can be cured may indicate in situ activation of both the T cell receptor and the costimulatory pathway.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Renner, C -- Jung, W -- Sahin, U -- Denfeld, R -- Pohl, C -- Trumper, L -- Hartmann, F -- Diehl, V -- van Lier, R -- Pfreundschuh, M -- New York, N.Y. -- Science. 1994 May 6;264(5160):833-5.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Medizinische Klinik und Poliklinik, Universitat des Saarlandes, Homburg, Germany.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/8171337" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Antibodies, Bispecific/immunology/*therapeutic use
;
Antibodies, Monoclonal
;
Antigens, CD28/*immunology
;
Antigens, CD3/*immunology
;
Antigens, CD30/*immunology
;
Hodgkin Disease/immunology/*therapy
;
Humans
;
Lymphocyte Activation
;
Mice
;
Mice, SCID
;
Neoplasm Transplantation
;
Receptors, Antigen, T-Cell/immunology
;
T-Lymphocyte Subsets/*immunology
;
Transplantation, Heterologous
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
